Amendments to the Claims:

This listing will replace all prior versions and listings of claims in the application:

Listing of Claims:

1. (Currently Amended) A compound according to formula I:



(I)

wherein:

R^1 and R^3 are each independently H, lower alkyl, $-SO_3H$, or $-PO_3H_2$, ;

R^2 is selected from hydrogen, $-SO_3H$ or $-PO_3H$

or R^1 and R^2 together may form a 5-7-membered heterocycle ~~with the atoms to which they are bound form a methylenedioxy group~~ ;

or R^2 and R^3 together may form a 5-7-membered heterocycle ~~with the atoms to which they are bound form a methylenedioxy group~~; and

X^1 is bound in the 2- or 3- position and is of the formula :

$Ar\text{-}X^3$ wherein

Ar is furanyl, thienyl, pyridyl, cyclohexyl or benzyl andX^3 is a substituent on the ortho, meta, or para position of the phenyl ring and is H, C, N, NR', NR'R", NR'SO_2 R", or O; wherein R' and R" are each independently H, or lower alkyl ; and OR^1 is $O(CH_2)_nY$, wherein n is 1 to 2, Y is OR^4, NR^5R^6, $COOR^4$, or $CONR^5R^6$; or $O[CH_2CH(OH)CH_2]Y$, wherein Y is H, OR^4, NR^5R^6, $COOR^4$, or $CONR^5R^6$; wherein T is Y or $[CH_2CH(OH)CH_2]Y$, Y is H, OR^4, NR^5R^6, $COOR^4$, or $CONR^5R^6$ wherein R^4, R^5, and R^6 are each independently H, or lower alkyl, and R^5 and R^6 together may form a 5 to 7-membered ring; or pharmaceutically acceptable salts thereof, subject to the proviso that the compound according to formula I is not baicalein or 5, 6, 7-trihydroxyisoflavone or a compound wherein ~~X3~~ X^3 is hydroxyl-substituted phenyl.

2. (Cancelled)

3. (Cancelled)

4. (Original) The compound according to claim 1, wherein R^1, R^2 and R^3 are each independently-SO_3H or-PO_3H_2.

5. (Cancelled)

6. (Cancelled)

7. (Cancelled)

8. (Cancelled)

9. (Cancelled)

10. (Canceled)

11. (Previously Presented) The compound wherein the compound is 4'- (N,N-dimethylamino)-5, 6,7-trimethoxyflavone, 4'- (methylamino)-5, 6,7- trimethoxyflavone, 4'-[N-methyl-N-(3-methoxypropyl)amino)-5,6,7-trimethoxyflavone, 4'-[N,N-di-(2-hydroxyethyl)-amino)-5,7-dihydroxy-6-methoxyflavone, 4'-(2-hydroxyethylamino)-5,7-dihydroxy-6-methoxyflavone, 4'-(2-methanesulfonatoethylamino)-5,7-dihydroxy-6-methoxyflavone, 4'-[2-(N,N-diethylamino)ethylamino]-5,7-dihydroxy-6-methoxyflavone, 2,3-diphenyl-5,6,7-trimethoxychromone, 2,3-diphenyl-5,6,7-trihydroxychromone, 4'-(methylsulfonamido)-5,6,7-trimethoxyflavone, 4'-[2-(N,N-diethylamino)ethoxy]-6,7-methylenedioxy-5-hydroxy-flavone, 4'-(2,3-dihydroxy-propyloxy)-5,6,7-trimethoxyflavone, or 4'-(Carbmethoxymethoxy)-5,6,7-trimethoxyflavone.

12. (Original) A pharmaceutical formulation comprising a compound according to claim 1 and at least one pharmaceutically acceptable carrier, diluent, or excipient.

13. (Cancelled)

14. (Currently Amdended) A method of treating diseases associated with overproduction of TNF-α selected from the group consisting of rheumatoid arthritis, Crohn's disease, and ulcerative colitis, comprising administering to a subject in need thereof an effective amount of a compound according to claim 1.

15. (Cancelled)

16. (Cancelled)

17. (Cancelled)

18. (Previously Presented) A method of treating liver damage, lung damage or kidney damage or combinations thereof resulting from over production of TNF-α or superoxide anion raidacals comprising administering to a subject in need thereof an effective amount of a compound according to claim 1.

19. (Cancelled)

21. (Cancelled)

22. (Cancelled)

23. (Cancelled)

24. (Cancelled)

25. (Cancelled)

26. (Cancelled)

27. (Cancelled)

28. (Cancelled)

29. (Cancelled)

30. (Cancelled)

31. (Currently Amended) A method of treating conditions selected from the group consisting of diseases associated with the overproduction of TNF-α, overproduction of superoxide anion radical and combinations thereof, comprising administering to a subject in need thereof, a pharmaceutical composition comprising a therapeutically effective amount of a compound of the formula V:



(V)

wherein: ~~R^7,R^8, and R^9~~ R^7, R^8, and R^9 are each independently H, lower alkyl,-SO_3H,-PO_3H_2; or R^7 and R^8 together may form a 5-7-membered heterocycle ~~with the atoms to which they are bound form a methylenedioxy group~~ or

R^8 and R^9 together may form a 5-7-membered heterocycle ~~with the atoms to which they are bound form a methylenedioxy group~~ ;

X^1 is a substituent on the ortho, meta, or para position of the phenyl ring and is H, C, NH_2, $NHCOCH_3$, or OR^{10}, wherein R^{10} is H, lower alkyl, or pharmaceutically

acceptable salts thereof.

32. (Cancelled)
33. (Cancelled)
34. (Cancelled)
35. (Cancelled)
36. (Cancelled)
37. (Cancelled)
38. (Cancelled)

39. (previously presented) The method according to claim 31, wherein the compound is 5,6,7- trihydroxyisoflavone, 4',5,6,7- tetrahydroxyflavone, or 4'-amino -5,7-dihydroxy-6-methoxy flavone.

40. (Cancelled)
41. (Cancelled)
42. (Cancelled)
43. (Cancelled)

44. (Currently amended) The method according to claim 31, wherein the pharmaceutical composition is administered in combination with at least one other therapeutic agent useful for the ~~prevention or~~ treatment of conditions associated with overproduction of TNF-α, and liver damage, lung damage or kidney damage. [[.]]

45. (Original) The method according to claim 31, wherein the pharmaceutical composition is administered orally or parenterally.

46. (previously presented) A method of treating conditions selected from the group consisting of diseases associated with the overproduction of TNF-α and combinations thereof, comprising administering to a subject in need thereof, a pharmaceutical composition comprising a therapeutically effective amount of a compound selected from the group

consisting of baicalein-6-sulfate, baicalein-6,7-disulfate, bacalein-6-phosphate, bacalein-6,7-diphosphate, baicalein- 5,6, 7-triphosphate, sodium and potassium salt derivatives thereof, and pharmaceutically acceptable salts thereof.

47. (Cancelled)

48. (Cancelled)

49 (Cancelled)

50 (Cancelled)

51. (Cancelled)

52. (Currently amended) The method according to claim 46, wherein the pharmaceutical composition is administered in combination with at least one other therapeutic agent useful for the ~~prevention or~~ treatment of conditions associated with overproduction of TNF-α.

53. (Original) The method according to claim 44, wherein the pharmaceutical composition is administered orally or parentally.

54. (previously presented) A method of treating conditions selected from the group consisting of diseases associated with the overproduction of TNF-α, and combinations thereof, comprising administering to a subject in need thereof, a pharmaceutical composition comprising a therapeutically effective amount of compound as in Claim 11.

55. (Cancelled)
56. (Cancelled)
57. (Cancelled)
58. (Cancelled)
59. (Cancelled)

60. (Currently amended) A method of treating liver damage, lung damage or kidney damage resulting from over production of TNF-α or superoxide anion raidacals which comprises administering to a subject in need thereof a therapeutically effective amount of a compound of the formula:



wherein ~~R_1~~ R^1 is selected from hydrogen and alkyl;

~~R_2~~ R^2 is selected from hydrogen, lower alkyl and sulfate or ~~R_1 and R_2~~ R^1 and R^2 together may form a 5-membered heterocycle ~~with the atoms to which they are bound form a methylenedioxy group~~;

~~R_3~~ R^3 is selected from hydrogen, lower alkyl and sulfate;

~~X_1~~ X^1 is selected from hydrogen, phenyl and substituted phenyl wherein the substituent is hydroxyl, alkoxy, amino, mono or dialkyl substituted amino, hydroxyl alkoxy, or aminoalkoxy

and ~~X_2~~ X^2 is selected from hydrogen and phenyl, and ~~X1 and X2~~ X^1 and X^2 ~~can not~~ cannot both be phenyl.